Explore / Peer-reviewed article
Peer-reviewed articleOpen access

The 4-alkyl chain length of 2,5-dimethoxyamphetamines differentially affects in vitro serotonin receptor actions versus in vivo psychedelic-like effects.

Luethi DiD, Glatfelter GC, Pottie EiD, Sellitti F, Maitland ADiD, Gonzalez NRiD, Kryszak LAiD, Jackson SN, Hoener MCiD, Stove CPiD, Liechti MEiD, Smieško MiD, Baumann MH, Simmler LDiD, Rudin DiD

Molecular psychiatryNov 5, 2025License: open accessSwitzerland, Belgium2 citationsDOI: 10.1038/s41380-025-03325-1

Abstract

Various ring-substituted α-methylphenethylamines (i.e., amphetamines) produce psychedelic-like effects that are primarily mediated by activity at 5-hydroxytryptamine 2A (5-HT<sub>2A</sub>) receptors. Small lipophilic substituents at the 4-position of the 2,5-dimethoxyamphetamine core structure can greatly enhance the clinical potency of such derivatives. Here, we studied the effects of various 4-alkylated 2,5-dimethoxyamphetamines (4-methyl, 4-ethyl, 4-propyl, 4-butyl, 4-amyl) on in vitro receptor activities and in vivo psychedelic-like effects in mice. The acute effects of the compounds were examined using the mouse head-twitch response (HTR) assay, a proxy for psychedelic-like drug actions. Overall, the series primarily interacted with 5-HT<sub>2</sub> receptor subtypes, with increasing 4-alkyl chain length associated with increased affinity at 5-HT<sub>2A</sub> receptors. For all three in vitro functional readouts assessed, the 4-propyl analog produced the highest potencies for 5-HT<sub>2A</sub> receptor activation (1-9 nM), but smaller and longer chain lengths displayed comparable activities (2-56 nM). In mice, the compounds displayed variable maximal HTR counts (23-119) and potencies (0.42-2.76 mg/kg), with the 4-propyl and 4-methyl compounds being the most potent and efficacious, respectively. Analysis of drug concentrations in mouse plasma, brain tissue, and brain dialysate samples revealed that derivatives with longer alkyl chains (i.e., butyl, amyl) require higher systemic doses to achieve concentrations comparable to those of short-chain analogs. These findings demonstrate that extending the 4-position alkyl chain beyond a propyl group reduces in vivo potency and efficacy, in part due to pharmacokinetic parameters.

Topics & conditions

Detected automatically by Psychedelic Commons from the title and abstract, not labels from the source. They may be incomplete.

Psychedelics

Psychedelic Commons aggregates metadata from open sources and links back to the original. Rights remain with the authors and publishers. Something wrong with this record? Report a problem.